Advanced breast cancer drugs could also target cholangiocarcinoma

Scan reveals cholangiocarcinoma. Getty/mr.suphachai praserdumrongchai

By Storm Newton, PA Media

Drugs that target advanced breast cancer could be beneficial for patients with a rare cancer that affects parts of the digestive system, a trial has found.

Tucatinib and trastuzumab are recommended by the National Institute for Health and Care Excellence as an option for patients with HER2‑positive locally advanced or metastatic breast cancer who have had two or more anti‑HER2 treatment therapies.